Nivolumab,Relatlimab
BMS
['047 ,(-nct047),(-0.047%),(-2047)', 'relativity,047', 'melanoma', 'nivo', 'nivo+rela']
#melanomaorals #asco23 relativity-047 update, nivo+rela continue to show benefit as upfront therapy for metastatic/unrestable melanoma pts with similar safety signals. an interesting subsequent 2l line analysis showed no major concerns for salvage therapies with ici or braf/meki 
Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, father, IO fan, trialist and skin cancer specialist to be!